Manila Times Business
Syncromune Presents Multi-Modal Efficacy Assessment Framework at Inaugural Gustave Roussy Intratumoral Immunotherapy Symposium
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2026 (GLOBE NEWSWIRE) -- Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™, an investigational in situ multi-target immunotherapy platform for solid tumors, today announced that Executive Chairman and Chief Innovation Officer Charles Link, M.D., presented and served as a panelist at the inaugural Intratumoral Immunotherapy Symposium 2026. The event was hosted by Gustave Roussy in partnership wi
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →